Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.70 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355333 | 0.93 | AVPR1A (0.75) | AVPR1AAVPR2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL14580395 | 0.90 | AVPR1A (0.73) | AVPR1AAVPR2OXTRTMEM97SIGMAR1 | |
| SCHEMBL4360665 | 0.85 | AVPR1A (0.82) | AVPR1AAVPR2OXTR | |
| SCHEMBL4362913 | 0.85 | AVPR1A (0.82) | AVPR1AAVPR2OXTR | |
| SCHEMBL4364833 | 0.85 | AVPR1A (0.71) | AVPR1AAVPR2OXTR | |
| SCHEMBL4359406 | 0.83 | AVPR1A (0.84) | AVPR1AAVPR2ALDH1A1TSHROXTR | |
| SCHEMBL4355322 | 0.83 | AVPR1A (0.80) | AVPR1AAVPR2OXTR | |
| SCHEMBL4359530 | 0.82 | AVPR1A (1.00) | AVPR1AAVPR2OXTR | |
| SCHEMBL4357898 | 0.82 | AVPR1A (0.85) | AVPR1AAVPR2OXTR | |
| SCHEMBL4359608 | 0.81 | AVPR1A (0.64) | AVPR1AAVPR2CYP2D6ALDH1A1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR2 2/4885CYP2D6 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.